TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms that no legally binding agreement has been ...

Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

SEC Filings provided by EDGAR Online, Inc.

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

Während seiner dreimonatigen Kündigungsfrist wurde er freigestellt – er musste damit keine Arbeitsleistungen mehr erbringen. Beschäftigter handelt nicht »böswillig« In der Entscheidung der ...

After hours: 7:59:57 p.m. EST Loading Chart for MRK ...